Your browser doesn't support javascript.
loading
Preventing occludin tight-junction disruption via inhibition of microRNA-193b-5p attenuates viral load and influenza-induced lung injury.
Vaswani, Chirag M; Varkouhi, Amir K; Gupta, Sahil; Ektesabi, Amin M; Tsoporis, James N; Yousef, Sadiya; Plant, Pamela J; da Silva, Adriana L; Cen, Yuchen; Tseng, Yi-Chieh; Batah, Sabrina S; Fabro, Alexandre T; Advani, Suzanne L; Advani, Andrew; Leong-Poi, Howard; Marshall, John C; Garcia, Cristiana C; Rocco, Patricia R M; Albaiceta, Guillermo M; Sebastian-Bolz, Steffen; Watts, Tania H; Moraes, Theo J; Capelozzi, Vera L; Dos Santos, Claudia C.
  • Vaswani CM; Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada.
  • Varkouhi AK; Department of Chemistry and Environmental Science, New Jersey Institute of Technology, Newark, NJ, USA.
  • Gupta S; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada; Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Faculty of Medicine, School of Medicine, The University of Queensland, Herston, QLD 4006, Australia.
  • Ektesabi AM; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada; Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Tsoporis JN; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada.
  • Yousef S; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada.
  • Plant PJ; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada.
  • da Silva AL; Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; COVID-19 Virus Network from Ministry of Science, Technology, and Innovation, Brazilian Council for Scientific and Technological Development, and Foundatio
  • Cen Y; Program in Translational Medicine, SickKids Research Institute, Toronto, ON, Canada.
  • Tseng YC; Program in Translational Medicine, SickKids Research Institute, Toronto, ON, Canada.
  • Batah SS; Department of Pathology and Legal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
  • Fabro AT; Department of Pathology and Legal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
  • Advani SL; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada.
  • Advani A; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada.
  • Leong-Poi H; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada; Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Marshall JC; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada; Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Garcia CC; Laboratory of Respiratory, Exanthematic Viruses, Enterovirus and Viral Emergencies, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil; Integrated Research Group on Biomarkers. René Rachou Institute, FIOCRUZ Minas, Belo Horizonte, Brazil.
  • Rocco PRM; Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; COVID-19 Virus Network from Ministry of Science, Technology, and Innovation, Brazilian Council for Scientific and Technological Development, and Foundatio
  • Albaiceta GM; Departamento de Biología Funcional, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain; Unidad de Cuidados Intensivos Cardiológicos, Hospital Universitario Central de Asturias, Oviedo, Spain; CIBER-Enfermedades Respiratorias, Instituto de Salud Carl
  • Sebastian-Bolz S; Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Watts TH; Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Moraes TJ; Program in Translational Medicine, SickKids Research Institute, Toronto, ON, Canada; Department of Pediatrics University of Toronto and Respirology, Hospital for Sick Children, Toronto, ON, Canada.
  • Capelozzi VL; Department of Pathology, University of São Paulo, São Paulo, Brazil.
  • Dos Santos CC; Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada; Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Laboratory Me
Mol Ther ; 31(9): 2681-2701, 2023 09 06.
Article en En | MEDLINE | ID: mdl-37340634
ABSTRACT
Virus-induced lung injury is associated with loss of pulmonary epithelial-endothelial tight junction integrity. While the alveolar-capillary membrane may be an indirect target of injury, viruses may interact directly and/or indirectly with miRs to augment their replication potential and evade the host antiviral defense system. Here, we expose how the influenza virus (H1N1) capitalizes on host-derived interferon-induced, microRNA (miR)-193b-5p to target occludin and compromise antiviral defenses. Lung biopsies from patients infected with H1N1 revealed increased miR-193b-5p levels, marked reduction in occludin protein, and disruption of the alveolar-capillary barrier. In C57BL/6 mice, the expression of miR-193b-5p increased, and occludin decreased, 5-6 days post-infection with influenza (PR8). Inhibition of miR-193b-5p in primary human bronchial, pulmonary microvascular, and nasal epithelial cells enhanced antiviral responses. miR-193b-deficient mice were resistant to PR8. Knockdown of occludin, both in vitro and in vivo, and overexpression of miR-193b-5p reconstituted susceptibility to viral infection. miR-193b-5p inhibitor mitigated loss of occludin, improved viral clearance, reduced lung edema, and augmented survival in infected mice. Our results elucidate how the innate immune system may be exploited by the influenza virus and how strategies that prevent loss of occludin and preserve tight junction function may limit susceptibility to virus-induced lung injury.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: MicroARNs / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A / Lesión Pulmonar Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: MicroARNs / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A / Lesión Pulmonar Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article